Hertzel C. Gerstein researcher
Gerstein, Hertzel C.
VIAF ID: 10076281 (Personal)
Permalink: http://viaf.org/viaf/10076281
Preferred Forms
- 200 _ | ‡a Gerstein ‡b Hertzel C.
- 100 1 _ ‡a Gerstein, Hertzel C
- 100 1 _ ‡a Gerstein, Hertzel C.
-
-
- 100 0 _ ‡a Hertzel C. Gerstein ‡c researcher
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Evidence-based diabetes care | |
Long-term effects of intensive glucose lowering on cardiovascular outcomes | |
Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology | |
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study | |
Making a Difference With Diabetes Research and Care: Table 1 | |
Maternal antioxidants prevent β-cell apoptosis and promote formation of dual hormone-expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure | |
Maturation of CGM and Glycemic Measurements Beyond HbA1c-A Turning Point in Research and Clinical Decisions. | |
Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial | |
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity | |
Microvascular outcomes in type 2 diabetes – Authors' reply | |
Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. | |
Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. | |
More insights on the dysglycaemia-cardiovascular connection | |
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. | |
Novel Biomarkers for Change in Renal Function in People With Dysglycemia | |
Numbers can save lives: Janice Pogue (1962-2016). | |
Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans | |
Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene | |
Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. | |
Perceived exertion with glucose ingestion in adolescent males with IDDM | |
Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study | |
Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial | |
Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach | |
Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. | |
Postępy w chorobach wewnętrznych / Jadwiga Wedzicha [i inni] // MP Medycyna Praktyczna. - 9 (367) 2021, strony 16-26. | |
Postępy w chorobach wewnętrznych - najważniejsze dokonania ostatnich lat : opinie ekspertów MIRCIM. | |
Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion. | |
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid | |
Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial | |
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program | |
Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. | |
Preventive medicine in a diabetes clinic: an opportunity to make a difference | |
Preventive medicine in people at high risk for chronic disease: the value of identifying and treating diabetes. Rebuttal to Marshall | |
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association | |
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation | |
Prospective associations of vitamin D with β-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study | |
Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus | |
Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. | |
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo | |
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. | |
Reducing the risk of cardiovascular complications in the long-term care setting | |
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. | |
Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. | |
Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial | |
Relationship of epicardial fat thickness and fasting glucose | |
Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease | |
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. | |
Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review | |
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201. | |
Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915-2922. | |
Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). | |
Risk factors for acute myocardial infarction in Indians: a case-control study | |
Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids | |
Risk Prediction for Early CKD in Type 2 Diabetes | |
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus | |
Rosiglitazone and cardiovascular outcomes: is there a clear answer? | |
Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis | |
Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth | |
Screening for postpartum thyroid dysfunction. | |
Self-Perceived Emotional Distress and Diabetes Risk Among Young Men. | |
Serious cardiovascular outcomes in diabetes: the role of hypoglycemia | |
Setting the record straight on TIDE: a lost opportunity for patients with diabetes | |
Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial | |
Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the PROMISE cohort study | |
Sleep quality and risk of diabetes and coronary artery disease among young men. | |
Spectrum of quality of life impairment in hypothyroidism. | |
Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. | |
"I take what I think works for me": a qualitative study to explore patient perception of diabetes treatment benefits and risks. |